After Pfizer (PFE) announced top-line data from the Phase 3 BENEGENE-2 trial of gene therapy fidanacogene elaparvovec for the treatment of adult males with moderately severe to severe hemophilia B, Wells Fargo analyst Mohit Bansal said he thinks the data "looks competitive" when compared to uniQure’s (QURE) Hemgenix. Though Pfizer "may be 1-2 yrs behind the recently approved Hemgenix," he thinks Pfizer’s "commercial firepower could be helpful in catching up," added Bansal, who has an Overweight rating and $54 price target on Pfizer shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- MRK Slips Despite New Chinese Approval
- 2 Healthcare Stocks Analysts Favor Ahead of a Recession Year
- Pfizer discloses 5.38M share stake in Oric Pharmaceuticals
- Pfizer data has positive read-through for uniQure, says H.C. Wainwright
- Pfizer announces topline results from Phase 3 study of fidanacogene elaparvovec